IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
Int J Mol Sci. 2023 Jan 22;24(3):2205. doi: 10.3390/ijms24032205.
Cardiovascular disease, the leading cause of death worldwide, has been characterized at the molecular level by alterations in gene expression that contribute to the etiology of the disease. Such alterations have been shown to play a critical role in the development of atherosclerosis, cardiac remodeling, and age-related heart failure. Although much is now known about the cellular and molecular mechanisms in this context, the role of epigenetics in the onset of cardiovascular disease remains unclear. Epigenetics, a complex network of mechanisms that regulate gene expression independently of changes to the DNA sequence, has been highly implicated in the loss of homeostasis and the aberrant activation of a myriad of cellular pathways. More specifically, non-coding RNAs have been gaining much attention as epigenetic regulators of various pathologies. In this review, we will provide an overview of the ncRNAs involved in cell-to-cell communication in cardiovascular disease, namely atherosclerosis, cardiac remodeling, and cardiac ageing, and the potential use of epigenetic drugs as novel therapeutic targets.
心血管疾病是全球范围内主要的致死原因,其分子水平的特征是基因表达的改变,这些改变促成了疾病的病因。这些改变被证明在动脉粥样硬化、心脏重构和与年龄相关的心力衰竭的发展中起着关键作用。尽管现在已经对这方面的细胞和分子机制有了很多了解,但表观遗传学在心血管疾病发病中的作用仍不清楚。表观遗传学是一个复杂的机制网络,它独立于 DNA 序列的变化来调节基因表达,它在失去体内平衡和无数细胞途径的异常激活中起着重要作用。更具体地说,非编码 RNA 作为各种病理的表观遗传调节剂越来越受到关注。在这篇综述中,我们将概述参与心血管疾病(即动脉粥样硬化、心脏重构和心脏老化)细胞间通讯的 ncRNAs,以及表观遗传药物作为新型治疗靶点的潜在用途。
Pharmacol Ther. 2018-11-13
Eur Heart J. 2018-8-1
Cardiovasc Res. 2019-10-1
Int J Mol Sci. 2023-11-11
Cell Mol Life Sci. 2017-9-14
Int J Biol Sci. 2019-1-24
J Mol Cell Cardiol. 2015-12
Biomedicines. 2023-7-6
Int J Mol Sci. 2023-4-26
Nanoscale Adv. 2022-1-10
Mol Ther Nucleic Acids. 2021-11-3
Nat Rev Cardiol. 2022-2
Redox Biol. 2021-10
Nat Rev Drug Discov. 2021-8